Literature DB >> 33971103

Stabilization of Nrf2 leading to HO-1 activation protects against zinc oxide nanoparticles-induced endothelial cell death.

Longbin Zhang1, Liyong Zou1, Xuejun Jiang2, Shuqun Cheng3, Jun Zhang1, Xia Qin4, Zhexue Qin5, Chengzhi Chen3,6, Zhen Zou1,6.   

Abstract

With the abundant production and wide application of zinc oxide nanoparticles (ZnONPs), the potential health risks of ZnONPs have raised serious concerns. Oxidative stress is recognized as the most important outcome of the toxicity induced by ZnONPs. The Nrf2-Keap1 system and its downstream antioxidative genes are the fundamental protective mechanisms for redox hemeostasis. However, the detailed mechanisms of Nrf2 activation in ZnONPs-treated endothelial cells and murine blood vessels have yet to be elucidated. Herein, we show that Nrf2 was activated and played a negative role in cell death induced by ZnONPs. Moreover, we demonstrate that HO-1 was the most extensively upregulated antioxidative gene-activated by Nrf2. Forced overexpression of HO-1, pharmacological activation of HO-1 with the agonists RTA-408 (omaveloxolone, an FDA-approved drug) and RTA-402 repressed cell death, and treatment with HO-1 antagonist SnPP exacerbated the cell death. Importantly, loss of HO-1 diminished the cytoprotective role induced by Nrf2 in ZnONPs-treated HUVEC cells, indicating that the Nrf2-HO-1 axis was the crucial regulatory mechanism for the antioxidative response in the context of ZnONPs-induced endothelial damage. Mechanistically, we demonstrate that the p62-Keap1 axis was not involved in the activation of Nrf2. Intriguingly, the degradation half-life of Nrf2 in HUVEC cells was increased from less than 1 h under quiescent conditions to approximately 6 h under ZnONPs treatment condition; moreover, ZnONPs treatment induced activation of Nrf2/HO-1 and accumulation of ubiquitin in the aorta ventralis of mouse, suggesting that the ubiquitin-proteasome system had been perturbed, which subsequently led to the stabilization of Nrf2 and activation of HO-1. This study might contribute to a better understanding of ZnONPs-associated toxicity.

Entities:  

Keywords:  HO-1; Nrf2; ZnONPs; antioxidative response; ubiquitin-proteasome system

Year:  2021        PMID: 33971103     DOI: 10.1080/17435390.2021.1919330

Source DB:  PubMed          Journal:  Nanotoxicology        ISSN: 1743-5390            Impact factor:   5.913


  4 in total

1.  Reciprocal regulation of NRF2 by autophagy and ubiquitin-proteasome modulates vascular endothelial injury induced by copper oxide nanoparticles.

Authors:  Na Li; Hang Du; Lejiao Mao; Ge Xu; Mengling Zhang; Yinzhen Fan; Xiaomei Dong; Lijun Zheng; Bin Wang; Xia Qin; Xuejun Jiang; Chengzhi Chen; Zhen Zou; Jun Zhang
Journal:  J Nanobiotechnology       Date:  2022-06-11       Impact factor: 9.429

Review 2.  Cytotoxicity of Metal-Based Nanoparticles: From Mechanisms and Methods of Evaluation to Pathological Manifestations.

Authors:  Peizheng Xiong; Xiangming Huang; Naijing Ye; Qunwen Lu; Gang Zhang; Shunlin Peng; Hongbo Wang; Yiyao Liu
Journal:  Adv Sci (Weinh)       Date:  2022-03-27       Impact factor: 17.521

3.  Recombinant Human Annexin A5 Alleviated Traumatic-Brain-Injury Induced Intestinal Injury by Regulating the Nrf2/HO-1/HMGB1 Pathway.

Authors:  Hejun Zhang; Yalong Gao; Tuo Li; Fanjian Li; Ruilong Peng; Cong Wang; Shu Zhang; Jianning Zhang
Journal:  Molecules       Date:  2022-09-06       Impact factor: 4.927

4.  Pre-validation of a reporter gene assay for oxidative stress for the rapid screening of nanobiomaterials.

Authors:  Sebastin Martin; Laura de Haan; Ignacio Miro Estruch; Kai Moritz Eder; Anne Marzi; Jürgen Schnekenburger; Magda Blosi; Anna Costa; Giulia Antonello; Enrico Bergamaschi; Chiara Riganti; David Beal; Marie Carrière; Olivier Taché; Gary Hutchison; Eva Malone; Lesley Young; Luisa Campagnolo; Fabio La Civita; Antonio Pietroiusti; Stéphanie Devineau; Armelle Baeza; Sonja Boland; Cai Zong; Gaku Ichihara; Bengt Fadeel; Hans Bouwmeester
Journal:  Front Toxicol       Date:  2022-09-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.